Expectations and clinical meaningfulness of randomized controlled trials
Alzheimer's & Dementia · 2023-06 · 19 (6) · 2730-2736
DOI: 10.1002/alz.12959 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 07.02.2023. Verfasst von Ronald C Petersen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS.
Abstract (Originalsprache)
Alzheimer's disease (AD) clinical trials are designed and powered to detect the impact of a therapeutic intervention, and there has been considerable discussion on what constitutes a clinically meaningful change in those receiving treatment versus placebo. The pathology of AD is complex, beginning many years before clinical symptoms are detectable, with multiple potential opportunities for therapeutic engagement. Introducing treatment strategies early in the disease and assessing meaningful change over the course of an 18‐month clinical trial are critical to understanding the value to an effective intervention. With new clinical trial data expected soon on emerging therapeutics from several AD studies, the Alzheimer's Association convened a work group of experts to discuss key considerations for interpreting data from cognitive and functional measures and what is considered a clinically meaningful benefit or meaningful slowing of this fatal disease. Our expectations of outcomes from therapeutic interventions in AD may need to be modified.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
- USC Alzheimer's Therapeutic Research Institute, San Diego, California, USA.
- Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
- Banner Sun Health Research Institute, Banner Health, Sun City, Arizona, USA.
- Eli Lilly and Company, Indianapolis, Indiana, USA.
- Center for Alzheimer Research and Treatment, Brigham and Women's Hospital and Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Förderung
- NIA NIH HHS
Zitieren
APA
Petersen, R. C., Aisen, P. S., Andrews, J. S., Atri, A., Matthews, B. R., Rentz, D. M., Siemers, E. R., Weber, C. J., & Carrillo, M. C. (2023). Expectations and clinical meaningfulness of randomized controlled trials. Alzheimer's & Dementia, 19(6), 2730-2736. https://doi.org/10.1002/alz.12959
Vancouver
Petersen RC, Aisen PS, Andrews JS, Atri A, Matthews BR, Rentz DM, et al. Expectations and clinical meaningfulness of randomized controlled trials. Alzheimer's & Dementia. 2023;19(6):2730-2736. doi:10.1002/alz.12959
BibTeX
@article{Petersen2023,
author = {Petersen, Ronald C and Aisen, Paul S and Andrews, J Scott and Atri, Alireza and Matthews, Brandy R and Rentz, Dorene M and Siemers, Eric R and Weber, Christopher J and Carrillo, Maria C},
title = {Expectations and clinical meaningfulness of randomized controlled trials},
journal = {Alzheimer's & Dementia},
year = {2023},
volume = {19},
number = {6},
pages = {2730--2736},
doi = {10.1002/alz.12959}
}
EUVIMED